TY - JOUR T1 - Metabolic and proteomic signatures of type 2 diabetes subtypes in an Arab population JF - medRxiv DO - 10.1101/2022.01.13.22269204 SP - 2022.01.13.22269204 AU - Shaza B. Zaghlool AU - Anna Halama AU - Nisha Stephan AU - Manonanthini Thangam AU - Emma Ahlqvist AU - Omar M. E. Albagha AU - Abdul Badi Abou⍰Samra AU - Karsten Suhre Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/01/13/2022.01.13.22269204.abstract N2 - Background Type 2 diabetes (T2D) has a heterogeneous etiology which is increasingly recognized to influence the risk of complications and choice of treatment. A data driven cluster analysis in four separate European populations of patients with type 2 diabetes identified four subtypes of severe insulin dependent (SIDD), severe insulin resistant (SIRD), mild obesity-related (MOD), and mild age-related (MARD) (Ahlqvist et al., Lancet Diabetes Endocrinology, 2018). Our aim was to extend this classification to the Arab population of Qatar and characterize the biological processes that differentiate these subtypes in relation to metabolomic and proteomic signatures.Methods The Ahlqvist et al. subtype clustering approach was applied to 631 individuals with T2D from the Qatar Biobank (QBB) and validated in an independent set of 420 participants from the same population. The association between blood metabolites (n=1,159) and protein levels (n=1,305) with each cluster were established.Findings The four subtypes of T2D were reproduced and validated in the population of Qatar. Cluster-specific metabolomic and proteomic associations revealed subtype-specific molecular processes. Activation of the complement system with many features of autoimmune diabetes and reduced 1,5-anhydroglucitol (1,5-AG) characterized SIDD, with evidence of impaired insulin signaling in SIRD, elevated leptin and fatty acid binding protein in MOD, whilst MARD appeared to be the healthiest subgroup.Interpretation We have replicated the four T2D clusters in an Arab population and identified distinct metabolic and proteomic signatures, providing insights into underlying etiology with the potential to deploy subtype-specific treatment options.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is supported by the Biomedical Research Program at Weill Cornell Medicine in Qatar, a program funded by the Qatar Foundation, and by QNRF grant NPRP11C-0115-180010. Qatar Biobank is supported by Qatar Foundation. The statements made herein are solely the responsibility of the authors. EA was funded by grants from the Swedish Research Council (2020-02191) and the Novo Nordisk foundation (NNF18OC0034408). Olink measurements in ANDIS were sponsored by Olink Proteomics (Uppsala, Sweden).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All QBB participants signed an informed consent form prior to their participation. The study was approved by HMC ethics committee and the QBB institutional review board. Use of the Qatar Biobank data was approved by the QBB IRB under reference Ex -2019-RES-ACC-0160-0083. All study participants provided written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe informed consent given by the study participants does not cover posting of participant level phenotype data in public databases. However, data are available upon request from Qatar Biobank (QBB) (https://www.qatarbiobank.org.qa/research/how-to-apply). Requests are submitted online and are subject to approval by the QBB board. ER -